27 11, 2023

Amphastar Pharmaceuticals, Inc. Powers Higher Towards Its August 9 All-Time High: Jump in Right Now?

By |2023-11-27T17:19:35+00:00November 27th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , , , |

By Leslie N. Masonson, MBA Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH), is a bio-pharmaceutical firm, that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products to its customers  in the United States, China, and France.  The company was incorporated in 1996 in Rancho Cucamonga, California where it is currently headquartered. It has [...]

27 06, 2023

One Analyst Predicts Canopy Growth is Headed to Zero, Should You Cut Losses and Move On?

By |2023-12-07T20:46:54+00:00June 27th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , |

At one point, Canopy Growth (CGC) was valued at $19 billion. The stock traded at over $50/share at its peak. But today? It sits at a mere $0.49/share. And as dramatic a fall from grace as this story already is, one analyst expects the true end is near. Benchmark analyst Mike Hickey believes Canopy [...]

15 05, 2023

Columbia Care is Up 20% After Earnings, But We Still See 3 Issues Investors Need to Be Aware Of

By |2023-12-07T20:50:59+00:00May 15th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , , |

Columbia Care Inc. (CCHWF) started the week with a bang, releasing its 1st quarter earnings report and exceeding analyst expectations. As a result, the stock has climbed more than 20%. But as you’ll discover below, there are still 3 major issues investors should be aware of. The cannabis company posted revenue of $124.54 million, [...]

18 04, 2023

Amneal Pharma Issues Guidance Over Market Forecasts, But We See 3 Things Holding the Stock Back

By |2023-12-07T20:57:13+00:00April 18th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stocks in the News|Tags: , , , |

Yesterday, Amneal Pharmaceuticals (AMRX) issued guidance for the first quarter of 2023 that came in over the consensus estimates. This sent shares trading as much as 14% higher in premarket trading. The stock opened Monday’s trading session at $1.34/share and closed at $1.63 for a nice single-day gain. The pharmaceutical company says that revenue [...]

Go to Top